Opus Genetics (IRD) Cash from Investing Activities Growth (5y) (2015 - 2024)
Opus Genetics (IRD) Cash from Investing Activities Growth (5y) (2015 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Opus Genetics | 291.93 Mn | 231.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 63.81% |
| Dec 31, 2021 | -15.11% |
| Dec 31, 2020 | 16.28% |
| Dec 31, 2019 | 43.95% |
| Sep 30, 2019 | 16.50% |
| Jun 30, 2019 | 109.08% |
| Mar 31, 2019 | -190.39% |
| Dec 31, 2018 | 45.25% |
| Sep 30, 2018 | 200.92% |
| Jun 30, 2018 | 53.02% |
| Mar 31, 2018 | 86.18% |
| Dec 31, 2017 | -28.49% |
| Sep 30, 2017 | 40.53% |
| Jun 30, 2017 | -44.23% |
| Mar 31, 2017 | 35.39% |
| Dec 31, 2016 | 25.48% |
| Sep 30, 2016 | -59.60% |
| Jun 30, 2016 | 29.53% |
| Mar 31, 2016 | 23.67% |
| Dec 31, 2015 | -31.94% |